315224-26-1

Basic information

• Product Name: INT-131
• Synonyms: INT-131;N-(3,5-DICHLORO-4-QUINOLIN-3-YLOXYPHENYL)-2,4-DIHYDROXYBENZENESULFONAMIDE;2,4-dichloro-N-(3,5-dichloro-4-(quinolin-3-yloxy)phenyl)benzenesulfonamide
• CAS NO: 315224-26-1
• Molecular Formula: C₂₁H₁₂Cl₄N₂O₃S
• Molecular Weight: 514.20858
• EINECS: -0
• Mol File: 315224-26-1.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 611.8±65.0 °C(Predicted)
• Appearance: /
• Density: 1.585±0.06 g/cm3(Predicted)
• PKA: 5.30±0.10(Predicted)
• CAS DataBase Reference: INT-131(CAS DataBase Reference)
• NIST Chemistry Reference: INT-131(315224-26-1)
• EPA Substance Registry System: INT-131(315224-26-1)

Safety Data

• Hazardous Substances Data: 315224-26-1(Hazardous Substances Data)

Usage

General Description

INT-131, also known as Pargluva, is a chemical compound that was developed as a potential treatment for type 2 diabetes. It works by targeting the PPAR-alpha and PPAR-gamma receptors, which are involved in the regulation of glucose and lipid metabolism. INT-131 has been shown to improve insulin sensitivity and lower blood sugar levels in diabetic patients, making it a promising candidate for the treatment of this condition. However, clinical trials have shown some safety concerns, including an increased risk of heart failure, and as a result, further development of INT-131 as a diabetes treatment has been discontinued.

Upstream product

• 580-18-7 3-hydroxyquinoline 
• 20098-48-0 3,4,5-trichloronitrobenzen 
• 315228-23-0 3-(2,6-dichloro-4-nitrophenoxy)quinoline 
• 315228-24-1 3,5-dichloro-4-(quinolin-3-yloxy)aniline 
• 16271-33-3 2,4-Dichlorobenzenesulfonyl chloride 

Downstream Products

• 1185842-41-4 C₇H₈O₃S*C₂₁H₁₂Cl₄N₂O₃S 
• 1220390-12-4 BrH*C₂₁H₁₂Cl₄N₂O₃S 
• 849738-78-9 2,4-dichloro-N-[3,5-dichloro-4-(quinolin-3-yloxy)-phenyl]-benzenesulfonamide benzenesulfonate salt 

Relevant articles and documents

Structure-Activity Relationship of 2,4-Dichloro-N-(3,5-dichloro-4-(quinolin-3-yloxy)phenyl)benzenesulfonamide (INT131) Analogs for PPARγ-Targeted Antidiabetics

Peroxisome proliferator-activated receptor γ (PPARγ) is a nuclear receptor central to fatty acid and glucose homeostasis. PPARγ is the molecular target for type 2 diabetes mellitus (T2DM) therapeutics TZDs (thiazolidinediones), full agonists of PPARγ with

SALTS AND POLYMORPHS OF A POTENT ANTIDIABETIC COMPOUND

Salts and polymorphs of a compound useful in the treatment of inflammatory and metabolic conditions and diseases are provided herein. In particular, the invention provides salts and polymorphs of a compound which modulates the expression and/or function of a peroxisome proliferator-activated receptor. The salts and polymorphs are useful for the treatment or prevention of conditions and disorders associated with energy homeostasis such as type II diabetes, lipid metabolism, adipocyte differentiation and inflammation.